Physician profile
Eric Lehnes
NPI 1396787875
$3,013.34
in general payments reported to CMS, 2019-2025
26 companies · $477 in 2025
The $477 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $39.33 · 2021: $245 · 2022: $508 · 2023: $352 · 2024: $280 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.74 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $1,111.71 | 2019-2024 | Myosure Tissue Removal Device, Aptima, Fluent Fluid Management System |
| Abbvie INC. | $309.75 | 2019-2023 | |
| Astellas Pharma US INC | $258.00 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $174.81 | 2019-2025 | |
| Pfizer INC. | $113.11 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $112.60 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $88.95 | 2021-2025 | |
| Evofem Biosciences, INC. | $81.04 | 2021-2025 | Phexxi, Solosec, Phexx |
| Therapeuticsmd, INC. | $71.72 | 2019-2021 | |
| Coopersurgical, INC. | $65.78 | 2019-2025 | Paragard T 380a, Advincula Delineator Uterine Manipulator |
| Organon LLC | $64.75 | 2022-2024 | Nexplanon |
| Myovant Sciences INC. | $62.19 | 2022 | |
| Exact Sciences Corporation | $60.31 | 2023-2024 | Cologuard Collection Kit |
| Roche Diagnostics Corporation | $60.23 | 2019 | |
| Daiichi Sankyo INC. | $59.16 | 2021-2023 | Injectafer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $56.37 | 2019 | |
| Millicent US INC | $50.98 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Medtronic, INC. | $33.71 | 2021-2022 | |
| Amgen INC. | $30.60 | 2021-2023 | Evenity, Prolia |
| Sage Therapeutics, LLC | $30.19 | 2024-2025 | Zurzuvae |
| Radius Health, INC. | $29.33 | 2022-2023 | |
| Intuitive Surgical, INC. | $26.54 | 2025 | |
| Smith+Nephew, INC. | $18.31 | 2024 | Pico 7 |
| Exeltis, USA INC. | $15.00 | 2022 | |
| Minerva Surgical, INC | $14.63 | 2019 | |
| Agile Therapeutics, INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lehnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.